Top

Published in:

01-08-2014 | Topic Review

Diffuse intrinsic pontine glioma: a reassessment

Authors: Nathan J. Robison, Mark W. Kieran

Published in: Journal of Neuro-Oncology | Issue 1/2014

Abstract

Diffuse intrinsic pontine glioma (DIPG) is a disease of childhood whose abysmal prognosis has remained unchanged for over 50 years. Biologic investigation has been stymied by lack of pretreatment tissue, as biopsy has been reserved for atypical cases. Recent advances in surgical and molecular-analytic techniques have increased the safety and potential utility of biopsy; brainstem biopsy has now been incorporated into several prospective clinical trials. These and other recent efforts have yielded new insights into DIPG molecular pathogenesis, and opened new avenues for investigation.

Harris W (1926) A case of pontine glioma, with special reference to the paths of gustatory sensation. Proc R Soc Med 19:1–5PubMedCentralPubMed

Lassman LP, Arjona VE (1967) Pontine gliomas of childhood. Lancet 1:913–915PubMed

Hargrave D, Bartels U, Bouffet E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7:241–248PubMed

Bradley KA, Zhou T, McNall-Knapp RY, Jakacki RI, Levy AS, Vezina G, Pollack IF (2013) Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children’s oncology group phase 2 study. Int J Radiat Oncol Biol Phys 85:e55–e60PubMedCentralPubMed

Pollack IF, Stewart CF, Kocak M, Poussaint TY, Broniscer A, Banerjee A, Douglas JG, Kun LE, Boyett JM, Geyer JR (2011) A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the pediatric brain tumor consortium. Neuro Oncol 13:290–297PubMedCentralPubMed

Jackson S, Patay Z, Howarth R, Pai Panandiker AS, Onar-Thomas A, Gajjar A, Broniscer A (2013) Clinico-radiologic characteristics of long-term survivors of diffuse intrinsic pontine glioma. J Neurooncol. doi:10.1007/s11060-013-1189-0 PubMed

Zarghooni M, Bartels U, Lee E, Buczkowicz P, Morrison A, Huang A, Bouffet E, Hawkins C (2010) Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 28:1337–1344PubMed

Lassiter KR, Alexander E Jr, Davis CH Jr, Kelly DL Jr (1971) Surgical treatment of brain stem gliomas. J Neurosurg 34:719–725PubMed

Soler D, Borzyskowski M (1998) Lower urinary tract dysfunction in children with central nervous system tumours. Arch Dis Child 79:344–347PubMedCentralPubMed

10.

Zimmerman RA, Bilaniuk LT, Packer R, Sutton L, Samuel L, Johnson MH, Grossman RI, Goldberg HI (1985) Resistive NMR of brain stem gliomas. Neuroradiology 27:21–25PubMed

11.

Ramos A, Hilario A, Lagares A, Salvador E, Perez-Nuñez A, Sepulveda J (2013) Brainstem gliomas. Semin Ultrasound CT MR 34:104–112PubMed

12.

Yoshimura J, Onda K, Tanaka R, Takahashi H (2003) Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. Neurol Med Chir (Tokyo) 43:375–382; discussion 382

13.

Prabhu SP, Ng S, Vajapeyam S, Kieran MW, Pollack IF, Geyer R, Haas-Kogan D, Boyett JM, Kun L, Poussaint TY (2011) DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium. Childs Nerv Syst 27:11–18PubMedCentralPubMed

14.

Zukotynski KA, Fahey FH, Kocak M et al (2011) Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med 52:188–195PubMedCentralPubMed

15.

Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD (1993) Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children’s Cancer Group. Neurosurgery 33:1026–1029; discussion 1029–1030PubMed

16.

Fried I, Hawkins C, Scheinemann K et al (2012) Favorable outcome with conservative treatment for children with low grade brainstem tumors. Pediatr Blood Cancer 58:556–560PubMed

17.

Angelini P, Hawkins C, Laperriere N, Bouffet E, Bartels U (2011) Post mortem examinations in diffuse intrinsic pontine glioma: challenges and chances. J Neurooncol 101:75–81PubMed

18.

Fangusaro J, Finlay J, Sposto R et al (2008) Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer 50:312–318PubMed

19.

Giussani C, Poliakov A, Ferri RT et al (2010) DTI fiber tracking to differentiate demyelinating diseases from diffuse brain stem glioma. Neuroimage 52:217–223PubMed

20.

Jansen MHA, van Vuurden DG, Vandertop WP, Kaspers GJL (2012) Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev 38:27–35PubMed

21.

Mandell LR, Kadota R, Freeman C et al (1999) There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 43:959–964PubMed

22.

Packer RJ, Boyett JM, Zimmerman RA, Albright AL, Kaplan AM, Rorke LB, Selch MT, Cherlow JM, Finlay JL, Wara WM (1994) Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial. Cancer 74:1827–1834PubMed

23.

Janssens GO, Jansen MH, Lauwers SJ et al (2013) Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys 85:315–320PubMed

24.

Bouffet E, Raquin M, Doz F, Gentet JC, Rodary C, Demeocq F, Chastagner P, Lutz P, Hartmann O, Kalifa C (2000) Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer 88:685–692PubMed

25.

Korones DN, Fisher PG, Kretschmar C, Zhou T, Chen Z, Kepner J, Freeman C (2008) Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children’s Oncology Group phase II study. Pediatr Blood Cancer 50:227–230PubMed

26.

Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, Pollack IF (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol 13:410–416PubMedCentralPubMed

27.

Michalski A, Bouffet E, Taylor RE, Hargrave D, Walker D, Picton S, Robinson K, Pizer B, Bujkiewicz S (2010) The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. J Neurooncol 100:81–88PubMed

28.

Packer RJ, Prados M, Phillips P et al (1996) Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a childrens cancer group phase I/II study. Cancer 77:2150–2156PubMed

29.

Walker DA, Liu J, Kieran M, Jabado N, Picton S, Packer R, St Rose C, CPN Paris 2011 Conference Consensus Group (2011) A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol 15:462–468

30.

Saratsis AM, Kambhampati M, Snyder K et al (2013) Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes. Acta Neuropathol (Berl). doi:10.1007/s00401-013-1218-2

31.

Schwartzentruber J, Korshunov A, Liu X-Y et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231PubMed

32.

Khuong-Quang D-A, Buczkowicz P, Rakopoulos P et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol (Berl) 124:439–447

33.

Wu G, Broniscer A, McEachron TA et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. doi:10.1038/ng.1102

34.

Lewis PW, Müller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, Garcia BA, Muir TW, Becher OJ, Allis CD (2013) Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340:857–861PubMedCentralPubMed

35.

Paugh BS, Broniscer A, Qu C et al (2011) Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29:3999–4006PubMedCentralPubMed

36.

Barrow J, Adamowicz-Brice M, Cartmill M, MacArthur D, Lowe J, Robson K, Brundler M-A, Walker DA, Coyle B, Grundy R (2011) Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas. Neuro Oncol 13:212–222PubMedCentralPubMed

37.

Cage TA, Samagh SP, Mueller S, Nicolaides T, Haas-Kogan D, Prados M, Banerjee A, Auguste KI, Gupta N (2013) Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst. doi:10.1007/s00381-013-2101-0

38.

Grill J, Puget S, Andreiuolo F, Philippe C, Macconaill L, Kieran MW (2011) Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. doi:10.1002/pbc.24060 PubMed

39.

Kieran MW, Roberts CWM, Chi SN, Ligon KL, Rich BE, Macconaill LE, Garraway LA, Biegel JA (2012) Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer 59:1155–1157PubMedCentralPubMed

40.

Lee RS, Stewart C, Carter SL et al (2012) A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 122:2983–2988PubMedCentralPubMed

41.

Puget S, Philippe C, Bax DA et al (2012) Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PLoS One 7:e30313PubMedCentralPubMed

42.

Becher OJ, Hambardzumyan D, Walker TR et al (2010) Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma. Cancer Res 70:2548–2557PubMed

43.

Masui K, Suzuki SO, Torisu R, Goldman JE, Canoll P, Iwaki T (2010) Glial progenitors in the brainstem give rise to malignant gliomas by platelet-derived growth factor stimulation. Glia 58:1050–1065PubMed

44.

Monje M, Mitra SS, Freret ME et al (2011) Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci USA 108:4453–4458PubMedCentralPubMed

45.

Geoerger B, Aerts I, Casanova M et al (2012) A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors. In: 2012 ASCO Annual Meeting. J Clin Oncol 30:suppl; abstr 9519

46.

Pollack IF, Jakacki RI, Blaney SM et al (2007) Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol 9:145–160PubMedCentralPubMed

47.

Broniscer A, Baker JN, Tagen M et al (2010) Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol 28:4762–4768PubMedCentralPubMed

48.

Haas-Kogan DA, Banerjee A, Poussaint TY et al (2011) Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. Neuro Oncol 13:298–306PubMedCentralPubMed

49.

Paugh BS, Qu C, Jones C et al (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28:3061–3068PubMedCentralPubMed

50.

Buczkowicz P, Zarghooni M, Bartels U, Morrison A, Misuraca KL, Chan T, Bouffet E, Huang A, Becher O, Hawkins C (2013) Aurora kinase B is a potential therapeutic target in pediatric diffuse intrinsic pontine glioma. Brain Pathol Zurich Switz 23:244–253

51.

Vivanco I, Robins HI, Rohle D et al (2012) Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2:458–471PubMedCentralPubMed

52.

Broniscer A, Baker SD, Wetmore C et al (2013) Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res 19:3050–3058PubMedCentralPubMed

53.

Veringa SJE, Biesmans D, van Vuurden DG et al (2013) In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma. PLoS One 8:e61512PubMedCentralPubMed

54.

Chittiboina P, Heiss JD, Warren KE, Lonser RR (2014) Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. J Neurosurg Pediatr. doi:10.3171/2013.11.PEDS136

55.

Takakura K, Miki Y, Kubo O (1975) Adjuvant immunotherapy for malignant brain tumors in infants and children. Childs Brain 1:141–147PubMed

56.

Joshi BH, Puri RA, Leland P, Varricchio F, Gupta G, Kocak M, Gilbertson RJ, Puri RK (2008) Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. Neuro Oncol 10:265–274PubMedCentralPubMed

57.

Li G, Mitra SS, Monje M, Henrich KN, Bangs CD, Nitta RT, Wong AJ (2012) Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. J Neurooncol 108:395–402PubMedCentralPubMed

58.

Gilbertson RJ, Hill DA, Hernan R et al (2003) ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 9:3620–3624PubMed

59.

Warren KE, Killian K, Suuriniemi M, Wang Y, Quezado M, Meltzer PS (2011) Genomic aberrations in pediatric diffuse intrinsic pontine gliomas. Neuro Oncol. doi:10.1093/neuonc/nor190

60.

Geoerger B, Hargrave D, Thomas F et al (2011) Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol 13:109–118PubMedCentralPubMed

Title: Diffuse intrinsic pontine glioma: a reassessment
Authors: Nathan J. Robison
Mark W. Kieran
Publication date: 01-08-2014
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 1/2014
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-014-1448-8

ACC 2024 Congress

Springer Medicine

Diffuse intrinsic pontine glioma: a reassessment

Abstract

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma

Elderly patients aged 65–75 years with glioblastoma multiforme may benefit from long course radiation therapy with temozolomide

The relationship between working memory and cerebral white matter volume in survivors of childhood brain tumors treated with conformal radiation therapy

Clinical result of stereotactic radiosurgery for spinal metastasis from hepatocellular carcinoma: comparison with conventional radiation therapy

Erratum to: Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas

The overexpression of Epithelial cell adhesion molecule (EpCAM) in glioma